Table 1:
Enrolled and treated patients and disease characteristic
| Characteristic | All Patients (n=30) |
|---|---|
| Age at enrollment, y | |
| Median (range) | 62 (30-82) |
| Sex, N (%) | |
| Male | 19 (63) |
| Female | 11 (37) |
| Ethnicity, N (%) | |
| White | 28 (93) |
| Non-white | 2 (7) |
| Smoking history, N (%) | |
| Ever | 19 (63) |
| Never | 11 (37) |
| Smoking pack-year history among Ever smokers‡ | |
| Median (range) | 21.5 (3-60) |
| Alcohol use history, N (%) | |
| Ever | 14 (47) |
| Never | 16 (53) |
| ECOG Performance Status, N (%) | |
| 0 | 20 (67) |
| 1 | 10 (33) |
| Tumor Site, N (%) | |
| Larynx/Hypopharynx | 5 (17) |
| Oral Cavity | 25 (83) |
| AJCC 8th Edition Clinical disease stage, N (%)∥ | |
| III | 6 (20) |
| IV | 24 (80) |
| Days Neoadjuvant pembrolizumab to surgery† | |
| Median (range) | 40 (33-50) |
| Pathologic disease stage, N (%)† | |
| I-II | 5 (17.2) |
| III | 5 (17.2) |
| IV | 19 (65.5) |
| Extranodal extension (ENE), N (%)† | |
| ENE+ | 4 (13.8) |
| ENE- | 10 (34.5) |
| No Lymph node disease/no neck dissection | 15 (51.7) |
| Surgical margin status, N (%)† | |
| Positive | 4 (13.8) |
| Negative | 25 (86.2) |
| High Risk Pathology (ENE+ and/or positive margin) Status, N | |
| (%)† | |
| High Risk | 5 (17.2) |
| Not High Risk | 24 (82.8) |
‡
18 of 19 Ever smokers with pack-year smoking history data
∥
All patients M0
†
29 patients underwent definitive surgery; 1 patient refused surgery